HAUSFELD-&-CO-LLP
22.2.2021 09:02:10 CET | Business Wire | Pressemeddelelse
Fra 12. til 16. juli 2021 vil Competition Appeal Tribunal (CAT) tage stilling til, hvorvidt det skal godkende en begæring om kollektivt søgsmål/gruppesøgsmål (FX Claim UK ) indbragt af Phillip Evans, repræsentant for gruppen og tidligere formand for undersøgelseskomitéen ved den britiske Competition and Markets Authority. Søgsmålet er rettet mod enheder, der indgår i følgende bankkoncerner: Barclays, Citibank, The Royal Bank of Scotland/NatWest, JPMorgan, UBS og MUFG Bank.
Hver af bankerne har indrømmet overtrædelser af EU's konkurrencelovgivning i forbindelse med spothandel med valuta. Phillip Evans’ foreslåede krav søger kompensation fra bankerne på vegne af foreslåede grupper af personer, som hævdes at have lidt tab som følge af bankernes deltagelse i de pågældende overtrædelser.
CAT har udstedt en bekendtgørelse vedrørende dette retsmøde, som kan findes her .
Phillip Evans har engageret Hausfeld & Co LLP, et førende advokatfirma inden for tvister og konflikter, til at føre sagen. Hausfeld & Co LLP’s amerikanske søsterselskab, Hausfeld LLP, er et af de førende advokatfirmaerne i et lignende kollektivt søgsmål i USA, der inddrev mere end 2,3 mia. USD til personer, som var blevet berørt af overtrædelser mht. valutahandel i USA.
Phillip Evans' begæring anmoder CAT om at godkende kravet som kvalificeret til at fortsætte som kollektivt søgsmål på vegne af berettigede enheder og enkeltpersoner samt at godkende, at Phillip Evans agerer som repræsentant for gruppen.
CAT behandler Phillip Evans' begæring samtidigt med en anden begæring om kollektivt søgsmål relateret til valutahandelskarteller, der er fremsat af Michael O’Higgins FX Class Representative Limited. Det betyder, at CAT skal afgøre, hvilken af repræsentanterne der er bedst egnet til at handle som repræsentant for gruppen. Dette er første gang, at CAT er blevet bedt om at afklare en tvist af denne type i relation til kollektive søgsmål.
Enhver person med interesse i de to begæringer (herunder foreslåede medlemmer af gruppen) kan gøre indsigelse mod en af eller begge begæringerne eller bemyndigelsen af en af eller begge foreslåede repræsentanter ved at kontakte CAT og angive deres grunde til at gøre indsigelse senest kl. 16.00 den 4. maj 2021. Disse personer kan også anmode om tilladelse til at fremsætte skriftlige og/eller mundtlige bemærkninger under retsmødet i juli ved at sende en ansøgning herom, understøttet med begrundelser, til domstolen senest kl. 16.00 den 4. maj 2021.
Phillip Evans udtaler: "Det er i gruppens medlemmers interesse, at spørgsmål om certificering og valg af repræsentant afgøres så hurtigt som muligt. Det glæder mig, at domstolen har besluttet at afholde retsmødet om certificeringen i juli 2021."
Med forbehold for eventuelle ændringer som følge af Covid-19-pandemien vil retsmødet finde sted i Competition Appeal Tribunal, Salisbury Square House, 8 Salisbury Square, London EC4Y 8AP. For oplysninger om, hvordan du deltager i domstolens behandling af de to begæringer ved at aflevere skriftlige bemærkninger eller for at ansøge om at blive hørt ved retsmødet i juli, skal du gå ind på www.fxclaimuk.com og læse CATs bekendtgørelse her .
Slut
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210222005078/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum